VOTRIENT 200MG
DESCRIPTION
Votrient 200mg tablet(pazopanib) is a type Votrient 200mg tabletof protein kinase inhibitors. It is also indicated for the Votrient 200mg tablet treatment of advanced kidney cancer and soft tissue sarcoma
Votrient 200mg is an antineoplastics Votrient 200mg tabletmedications which interfere with the development and spreadness Votrient 200mg tablet of cancer cells in the body
USAGE
Votrient 200mg is used as a single agent toVotrient 200mg tablet treat the renel cell carcinoma and its advanced stage It works by preventing the activity of proteins which are interferes with the growth and spread Votrient 200mg tabletof cancer cells. Votrient 200mg tablet is also used Votrient 200mg tabletas a single regimen to Votrient 200mg tablet treat the Soft Tissue Sarcoma, (a type of cancer that occurs in the supportive tissue of the body). The cancer can develop in muscles, Votrient 200mg tabletblood vessels, fat tissue Votrient 200mg tabletor in other tissues that support, surround and protect organs
MECHANISM OF ACTION
Votrient 200mg is an effective inhibitor ofVotrient 200mg tablet protein kinase and selective multiple receptor tyrosine kinases (RTKsVotrient 200mg tablet that are described at the beginning of Votrient 200mg tablet signal transduction pathways that ready for the reproduction of tumor cells and affect processes critical to Votrient 200mg tabletcell survival andVotrient 200mg tablet tumor progression. RTKsVotrient 200mg tablet comes in the blockage and involves the receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3),Votrient 200mg tablet platelet-derived growth Votrient 200mg tablet factors (PDGFR-α and -β), and stem cell factor.
PHARMACOKINETIC
ABSORPTION
Fast GI absorption Votrient 200mg tablet with food and Votrient 200mg tabletBioavailability is 14-39%. Votrient 200mg tabletTime of high plasma concentration: 2-4 hr.
DISTRIBUTION
bounding of humanVotrient 200mg tablet protein of pazopanib 200mg is >99%.
METABOLISM
Mainly in the liver pazopanib Votrient 200mg tablet 200mg metabolized by CYP3A4 enzyme and to a lesser extent by CYP1A2 and CYP2C8 enzymes.
ELIMINATION
pazopanib primarily Votrient 200mg tabletexcreted through faeces approx 82%, 67% as unchanged drug and urine (<4%)with renal elimination. Votrient 200mg tabletTerminal Elimination half-life: Approx 31 hr.
PRODUCT DETAILS
Brand : Votrient
Ingredients : Pazopanib
Strength : 200mg
Manufactured : GlaxoSmithKline Pharmaceuticals
Package : 30 Tablets
DOSAGE AND ADMINISTARTION
Votrient Votrient 200mg tabletdosage for renal cell carcinomaVotrient 200mg tablet and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 200mg increments or decrements dose based on tolerance Votrient 200mg tabletbut max dose in adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient dose of 200mg once daily. Votrient 200mg tablet Votrient should be Votrient 200mg tablet taken on a empty stomachVotrient 200mg tablet (1hr before or 2hr after meals. Swallow theVotrient 200mg tablet medicine whole don’t chew/crush. Food interaction :Votrient 200mg tablet Avoid grapefruit juice or grapefruit juice.
OVERDOSAGE
overdose Votrient 200mg tablet of the drug can be upto 2000mg can be administrated and It is evaluated in clinical trials Votrient 200mg tablet and treatment of overdose with votrient should consist of Votrient 200mg tablet supportive measures and there is no specific antidote.
SIDE EFFECTS
Votrient 200mg tablet has certain side effects,Votrient 200mg tablet If any of the symptoms occrs or not cured then call the doctor immediately
MAJOR SIDE EFFECTS
Diarrhae; High blood pressure; Votrient 200mg tabletlow WBC; Elevated liver function test; Blood test abnormalities; increased Votrient 200mg tablet in bilirubin levels.
COMMON SIDE EFFECTS:
Nausea;Votrient 200mg tablet loss of appetite; fatigue; blood test abnormalities (low magnesium, low glucose); weakness, Votrient 200mg tablet stomach ache.
contact us:
EMAIL ID : millionhealthpharmaceuticals@gmail.com
PHONE NO : +91-9940472902
anticancer 
